English
新闻公告
More
化学进展 2013, Vol. 25 Issue (09): 1421-1428 DOI: 10.7536/PC130409 前一篇   后一篇

• 癌症化学预防专辑 •

癌症化学预防:过去,现在和未来

Michael B. Sporn*, Karen T. Liby   

  1. Department of Pharmacology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire 03755, USA
  • 收稿日期:2013-02-02 出版日期:2013-09-25 发布日期:2013-07-31
  • 通讯作者: Michael B. Sporn E-mail:michael.b.sporn@dartmouth.edu

A Mini-Review of Chemoprevention of Cancer——Past, Present, and Future

Michael B. Sporn*, Karen T. Liby   

  1. Department of Pharmacology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire 03755, USA
  • Received:2013-02-02 Online:2013-09-25 Published:2013-07-31
  • Contact: Michael B. Sporn E-mail:michael.b.sporn@dartmouth.edu

本文将对癌症化学预防的发展历史、研究现状及其未来前景作一简要评述,主要包括以下内容:癌症化学预防的科学基础,正在使用的癌症化学预防药物,对新合成药物的需求,以及面临的挑战等。本文尤其强调了联合用药在有效的癌症预防中的重要性。

We present a brief review of the history of chemoprevention of cancer, the present status of this field, and its prospects for the future. Topics covered are the scientific basis for chemoprevention of cancer, drugs in current use for chemoprevention of cancer, the need for new synthetic drugs, and the challenges ahead. The importance of the use of combinations of drugs for effective prevention is stressed.

中图分类号: 

()

[1] Bishop J M. Science, 1997, 278: 995
[2] Davidson N, Kensler T W. N. Engl. J. Med., 2011, 365: 2463—2464
[3] Sporn M B, Dunlop N M, Newton D L, Smith J M. Fed. Proc., 1976, 35: 1332—1338
[4] Sporn M B. Cancer Res., 1976, 36: 2699—2702
[5] Sporn M B. Lancet, 1996, 347: 1377—1381
[6] Sporn M B, Suh N. Nat. Rev. Cancer, 2002, 2: 537—543
[7] Sporn M B, Liby K T. Nat. Clin. Pract. Oncol., 2005, 2: 518—525
[8] Sporn M B. Nat. Clin. Pract. Oncol., 2006, 3: 364—373
[9] Albini A, Sporn M B. Nat. Rev. Cancer, 2007, 7: 139—147
[10] Liby K T, Yore M M, Sporn M B. Nat. Rev. Cancer, 2007, 7: 357—369
[11] Sporn M B. Nature, 2011, 471: S10—S11
[12] O'Shaughnessy J A, Kelloff G J, Gordon G B, Dannenberg A J, Hong W K, Fabian C J, Sigman C C, Bertagnolli M M, Stratton S P, Lam S, Nelson W G, Meyskens F L, Alberts D S, Follen M, Rustgi A K, Papadimitrakopoulou V, Scardino P T, Gazdar A F, Wattenberg L W, Sporn M B, Sakr W A, Lippman S M, von Hoff D D. Clin. Cancer Res., 2002, 8: 314—346
[13] Sporn M B. Cancer Res., 1991, 51: 6215—6218
[14] Hruban R H, Goggins M, Parsons J, Kern S E. Clin. Cancer Res., 2000, 6: 2969—2972
[15] Hingorani S R, Wang L, Multani A S, Combs C, Deramaudt T B, Hruban R H, Rustgi A K, Chang S, Tuveson D A. Cancer Cell, 2005, 7: 469—483
[16] Hingorani S R, Petricoin E F, Maitra A, Rajapakse V, King C, Jacobetz M A, Ross S, Conrads T P, Veenstra T D, Hitt B A, Kawaguchi Y, Johann D, Liotta L A, Crawford H C, Putt M E, Jacks T, Wright C V, Hruban R H, Lowy A M, Tuveson D A. Cancer Cell, 2003, 4: 437—450
[17] Pleasance E D, Stephens P J, O'Meara S, McBride D J, Meynert A, Jones D, Lin M L, Beare D, Lau K W, Greenman C, Varela I, Nik-Zainal S, Davies H R, Ordoñez G R, Mudie L J, Latimer C, Edkins S, Stebbings L, Chen L, Jia M, Leroy C, Marshall J, Menzies A, Butler A, Teague J W, Mangion J, Sun Y A, McLaughlin S F, Peckham H E, Tsung E F, Costa G L, Lee C C, Minna J D, Gazdar A, Birney E, Rhodes M D, McKernan K J, Stratton M R, Futreal P A, Campbell P J. Nature, 2010, 463: 184—190
[18] Sporn M B. Nature, 1980, 287: 107—108
[19] Meyskens F L Jr, McLaren C E, Pelot D, Fujikawa-Brooks S, Carpenter P M, Hawk E, Kelloff G, Lawson M J, Kidao J, McCracken J, Albers C G, Ahnen D J, Turgeon D K, Goldschmid S, Lance P, Hagedorn C H, Gillen D L, Gerner E W. Cancer Prev. Res., 2008, 1: 32—38
[20] Rendi M H, Suh N, Lamph W W, Krajewski S, Reed J C, Heyman R A, Berchuck A, Liby K, Risingsong R, Royce D B, Williams C R, Sporn M B. Cancer Res., 2004, 64: 3566—3571
[21] Tran K, Risingsong R, Royce D B, Williams C R, Sporn M B,Pioli P A, Gediya L K, Njar V C, Liby K T. Carcinogenesis, 2013, 34: 199—210
[22] Solomon S D, McMurray J J, Pfeffer M A, Wittes J, Fowler R, Finn P, Anderson W F, Zauber A, Hawk E, Bertagnolli M. N. Engl. J. Med., 2005, 352: 1071—1080
[23] Bresalier R S, Sandler R S, Quan H, Bolognese J A, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam M A, Baron J A. N. Engl. J. Med., 2005, 352: 1092—1102
[24] Wu X, Lippman S M. Nat. Rev. Cancer, 2011, 11: 879—885
[25] LaCroix A Z, Powles T, Osborne C K, Wolter K, Thompson J R, Thompson D D, Allred D C, Armstrong R, Cummings S R, Eastell R, Ensrud K E, Goss P, Lee A, Neven P, Reid D M, Curto M, Vukicevic S. J. Natl. Cancer Inst., 2010, 102: 1706—1715
[26] Andriole G L, Bostwick D G, Brawley O W, Gomella L G, Marberger M, Montorsi F, Pettaway C A, Tammela T L, Teloken C, Tindall D J, Somerville M C, Wilson T H, Fowler I L, Rittmaster R S. N. Engl. J. Med., 2010, 362: 1192—1202
[27] Chan A T. Prog. Chem., 2013, 25: 1450—1453
[28] Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, Gandini S. Cancer Prev. Res. (Phila), 2010, 3: 1451—1461
[29] Umar A, Dunn B K, Greenwald P. Nature Reviews Cancer, 2012, 12: 835—848
[30] Egner P A, Wang J B, Kensler T W, et al. Prog. Chem., 2013, 25: 1454—1461
[31] Sporn M B, Liby K T, Yore M M, Suh N, Albini A, Honda T, Sundararajan C, Gribble G W. Drug Dev. Res., 2007, 68: 174—182
[32] Sporn M B, Liby K T, Yore M M, Fu L, Lopchuk J M, Gribble G W. J. Nat. Prod., 2011, 74: 537—545
[33] Liby K T, Sporn M B. Pharmacol. Revs., 2012, 64: 972—1003
[34] Liby K, Royce D B, Williams C R, Risingsong R, Yore M M, Honda T, Gribble G W, Dmitrovsky E, Sporn T A, Sporn M B. Cancer Res., 2007, 67: 2414—2419
[35] Yore M M, Kettenbach A N, Sporn M B, Gerber S A, Liby K T. PLoS One, 2011, 6: 22862—22863
[36] Hong D S, Kurzrock R, Supko J G, He X, Naing A, Wheler J, Lawrence D, Eder J P, Meyer C J, Ferguson D A, Mier J, Konopleva M, Konoplev S, Andreeff M, Kufe D, Lazarus H, Shapiro G I, Dezube B J. Clin. Cancer Res., 2012, 18: 3396—3406
[37] Foulds L. Neoplastic Development. London ; New York: Academic P. 1969. 269
[38] Clark W H Jr. Acta Oncol., 1995, 34: 3—21
[39] Bissell M J, Hines W C. Nat. Med., 2011, 17: 320—329
[40] Coussens L M, Zitvogel L, Palucka A K. Science, 2013, 339: 286—291
[41] Albini A, Tosetti F, Li V W, Noonan D M, Li W W. Nat. Rev. Clin. Oncol., 2012, 9: 498—509
[42] Dawson M A, Kouzarides T. Cell, 2012, 150: 12—27
[43] Huang Y W, Kuo C T, Stoner K, Huang T H, Wang L S. FEBS Lett., 2011, 585: 2129—2136
[44] Lee J H, Khor T O, Shu L, Su Z Y, Fuentes F, Kong A N. Pharmacol. Ther., 2013, 137(2): 153—171
[45] Guttman M, Amit I, Garber M, French C, Lin M F, Feldser D, Huarte M, Zuk O, Carey B W, Cassady J P, Cabili M N, Jaenisch R, Mikkelsen T S, Jacks T, Hacohen N, Bernstein B E, Kellis M, Regev A, Rinn J L, Lander E S. Nature, 2009, 458: 223—227
[46] Lee J T. Science, 2012, 338: 1435—1439
[47] You J S, Jones P A. Cancer Cell, 2012, 22: 9—20
[48] Tsai H C, Baylin S B. Cell Res., 2011, 21: 502—517
[49] Gerlinger M, Rowan A J, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald N Q, Butler A, Jones D, Raine K, Latimer C, Santos C R, Nohadani M, Eklund A C, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal P A, Swanton C. N. Engl. J. Med., 2012, 366: 883—892
[50] Swanton C. Cancer Res., 2012, 72: 4875—4882
[51] Longo D L. N. Engl. J. Med., 2012, 366: 956—957
[52] Hopkins A L. Nat. Biotechnol., 2007, 25: 1110—1111
[53] Barabasi A L. Linked: How Everything is Connected to Everything Else and What it Means. New York: Penguin Group, 2000
[54] Prevention of Cancer in the Next Millennium: Report of the Chemoprevention Working Group to the American Association for Cancer Research. Cancer Res., 1999, 59: 4743—4758
[55] Levy E D, Landry C R, Michnick S W. Science, 2010, 328: 983—984

[1] 张荡, 王曦, 王磊. 生物酶驱动的微纳米马达在生物医学领域的应用[J]. 化学进展, 2022, 34(9): 2035-2050.
[2] 荆晓东, 孙莹, 于冰, 申有青, 胡浩, 丛海林. 肿瘤微环境响应药物递送系统的设计[J]. 化学进展, 2021, 33(6): 926-941.
[3] 王佳佳, 吴惠英, 董任峰, 蔡跃鹏. 基于微/纳马达的智能癌症诊断、递送及治疗[J]. 化学进展, 2021, 33(5): 883-894.
[4] 吴云雪, 张衡益, 刘育. 偶氮苯衍生物探针在乏氧细胞成像中的应用[J]. 化学进展, 2021, 33(3): 331-340.
[5] 郭珊, 周翔. 循环肿瘤细胞体内检测技术及其应用研究[J]. 化学进展, 2021, 33(1): 1-12.
[6] 郑秉得, 赵园园, 李洪才, 郑碧远, 柯美荣, 黄剑东*. 可激活抗癌光敏剂[J]. 化学进展, 2018, 30(9): 1403-1414.
[7] 卢金荣, 巨勇. 基于三萜骨架的超分子凝胶体系[J]. 化学进展, 2016, 28(2/3): 260-268.
[8] 黄笛, 项楠, 唐文来, 张鑫杰, 倪中华. 基于微流控技术的循环肿瘤细胞分选研究[J]. 化学进展, 2015, 27(7): 882-912.
[9] 范霄, 李艳艳, 刘迎亚, 曹昌盛, 李海涛. 单分子荧光技术在端粒和端粒酶研究中的应用[J]. 化学进展, 2014, 26(12): 1987-1996.
[10] 曾红梅, 陈万青. 中国癌症流行病学与防治研究现状[J]. 化学进展, 2013, 25(09): 1415-1420.
[11] Barbara K. Dunn. 乳腺癌预防的三期临床试验:雌激素靶向药物,选择性雌激素受体调控剂和芳香酶抑制剂[J]. 化学进展, 2013, 25(09): 1429-1449.
[12] Andrew T. Chan. 阿司匹林用于结直肠癌预防[J]. 化学进展, 2013, 25(09): 1450-1453.
[13] Patricia A. Egner, 王金兵, 朱源荣, Lisa P. Jacobson, Derek Ng, Alvaro Muñoz, Jed W. Fahey, 陈建国, 陈陶阳, 钱耕荪, John D. Groopman, Thomas W. Kensler*. 中国启东肝癌预防:黄曲霉毒素生物标志物研究的经验[J]. 化学进展, 2013, 25(09): 1454-1461.
[14] 黎钧耀. 癌症的营养干预研究[J]. 化学进展, 2013, 25(09): 1462-1479.
[15] Gary D. Stoner. 癌症预防的完全食物途径:以浆果为例[J]. 化学进展, 2013, 25(09): 1480-1491.
阅读次数
全文


摘要

癌症化学预防:过去,现在和未来